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Background/Aims: Solid organ transplant recipients fre-
quently report gastrointestinal symptoms, especially heart-
burn or dyspepsia. However, the prevalence of endoscopic 
erosive esophagitis (EE) and associated risk factors after 
transplantation are unknown. The aim of this study was to 
determine whether there was a high incidence of endoscopic 
findings of EE in solid organ transplant recipients. Methods: 
This retrospective case-control study included 256 of 3,152 
solid organ transplant recipients who underwent sequential 
screening upper endoscopic examinations and an equal 
number of controls. Results: Forty-four (17.2%) and 16 (6.2%) 
cases of EE were detected in the solid organ transplant and 
control groups, respectively (p<0.001). In the multivariate 
analysis, transplantation was significantly associated with 
EE (odds ratio [OR], 6.48; 95% confidence interval, 2.74 to 
15.35). Factors such as old age (OR, 1.17), the presence of 
a hiatal hernia (OR, 5.84), an increased duration of immuno-
suppression (OR, 1.07), and the maintenance administration 
of mycophenolate mofetil (OR, 4.13) were independently 
associated with the occurrence of EE in the solid organ 
transplant recipients. Conclusions: A significant increase in 
the incidence of endoscopically detected EE was observed 
in solid organ transplant recipients. This increased incidence 
was associated with the type and duration of the immuno-
suppressive therapy. (Gut Liver 2012;6:349-354)
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INTRODUCTION
According to literature, cancer is expected to surpass car-
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diovascular complications as the primary cause of death in 
transplanted patients within the next 2 decades.1,2 A nationwide 
cohort study from Sweden indicated a 3-fold increased risk of 
de novo tumors after solid organ transplantation (SOT).3 In ad-
dition, increased incidence of de novo esophageal cancer in the 
population of liver transplant recipients has been reported.4,5 
Accumulating evidence suggests that gastric acid is the major 
factor in the pathogenesis of gastroesophageal reflux disease 
and its complications, including erosive esophagitis (EE), Bar-
rett’s esophagus (BE), and esophageal adenocarcinoma.6,7 In the 
case of BE, which is recognized as a complication of EE and a 
pre-malignant condition that may lead to the development of 
esophageal adenocarcinoma, the proximal level of the squamo-
columnar junction no longer coincides with the gastroesopha-
geal junction.8,9
Gastrointestinal complications are frequent in SOT recipients 
and may involve any segment of the gastrointestinal tract. These 
disorders may be related to stress, infections, or exacerbation 
of pre-existing gastrointestinal pathology.10,11 In addition, im-
munosuppressive agents may cause gastrointestinal side effects, 
either directly or by favoring the development of bacterial or 
viral infection. Severe gastrointestinal disorders may develop in 
approximately 10% of SOT patients, eventually leading to graft 
loss and even patient death. Gastrointestinal complications may 
also result in reduction of the dose of immunosuppressant drugs 
and associated risk of organ rejection.10,11 According to various 
studies of patient-reported gastrointestinal symptoms, the ma-
jority of patients complained of symptoms such as indigestion, 
abdominal pain, constipation, diarrhea, or reflux.12,13 In particu-
lar, symptoms indicating the possibility of gastroesophageal re-
flux disease (heartburn or regurgitation) were reported to occur 
in 17% to 43% of renal transplant recipients during the post-
transplant period.14-16 Similarly, it was reported that incidence of 
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such symptoms rose from 3.4% to 27.6% after living donor liver 
transplantation.17,18 From these results, we hypothesized that a 
considerable number of transplant recipients are likely to show 
endoscopic evidence of EE or BE after transplantation. However, 
to date, no study using endoscopy to screen for EE in SOT re-
cipients, compared to a general non-transplant population, has 
been performed, and little is known regarding the occurrence of 
BE after organ transplantation. Indeed, a majority of investiga-
tions include endoscopic examination only for individuals with 
serious symptoms.14,15 Furthermore, there appears to be more 
interest in infectious than non-infectious esophagitis in SOT 
recipients. To overcome these limitations, it will be essential to 
evaluate the endoscopic findings of the gastroesophageal junc-
tion by using upper endoscopy as a screening tool for the popu-
lation undergoing SOT. 
The aim of the current study was to determine whether the 
incidence of endoscopic findings of EE or BE is high in SOT re-
cipients compared with a control population.
MATERIALS AND METHODS
1. Patients
We performed a case-control study at the Severance Hospital 
in Seoul, Korea from 2005 to 2010. The study population con-
sisted of subjects who had pre and post-transplant upper gastro-
intestinal endoscopy among 3,152 SOT (kidney, liver, pancreas, 
or heart transplantation) recipients. Patients were excluded for 
the following reasons: no baseline endoscopic examination 
prior to SOT (n=1,941), no data of follow-up endoscopy after 
transplantation (n=409), diagnosed of EE or BE in baseline en-
doscopy (n=133), previous gastric cancer or colorectal cancer 
(n=21), previous gastric surgery (n=9), high-risk symptoms such 
as occult blood, anemia, hematemesis, hematochezia, melena, 
vomiting, dysphagia, odynophagia, palpable mass, jaundice, or 
weight loss (n=70),19 current use of nonsteroidal anti-inflamma-
tory drugs (NSAIDs) or other ulcerogenic agents (n=99), or drug 
history of acid suppressive treatment within 6 months from 2nd 
endoscopic examination (n=214). The control group consisted 
of age- and gender matched patients who had undergone se-
quential endoscopies at intervals over 1 year as part of a health 
check-up during the same period and who had no endoscopi-
cally observed EE or BE in the first endoscopy. SOT patients 
(n=256), including 164 kidney, 85 liver, 5 pancreas, and 2 heart 
recipients, were selected using the procedure illustrated in Fig. 
1. Patients in an age- and gender-matched screening population 
(n=256) were enrolled as controls. Both the groups consisted of 
141 men (55.1%) and 115 women (44.9%); their mean age was 
47.3±6.9 years.
2. Endoscopic findings
Our hospital operates a digital filing system for endoscopic 
images. All digital endoscopic images were independently and 
retrospectively reviewed by two trained endoscopists to inves-
tigate the endoscopic findings, including hiatal hernia, EE, and 
BE. If any inconsistency in the assessment of the digital endo-
scopic images occurred, a final diagnosis was decided upon by a 
joint review of the digital endoscopic images. 
3. Hiatal hernia
Hiatal hernia was diagnosed when the distance between the 
gastroesophageal junction and the diaphragmatic hiatus was 1 
cm or more.20
4. EE
EE was diagnosed based on the Los Angeles Classification 
and was divided into three groups: none, mild (grades A and B), 
or severe (grades C and D).21
5. BE
The presence of BE was diagnosed based on the C&M crite-
Fig. 1. Selection of patients for the 
case-control study. 
SOT, solid organ transplantation; GI, 
gastrointestinal; NSAID, nonsteroi-
dal anti-inflammatory drug.
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ria.22 According to these criteria, BE is defined as the macro-
scopic identification, using a standard endoscopy examination, 
of abnormal columnar esophageal epithelium suggestive of a 
columnar-lined distal esophagus. The length of BE is measured 
(in centimeters) using the circumferential extent (the C extent) 
and the maximum extent (the M extent) above the gastroesoph-
ageal junction, identified as the proximal margin of the gastric 
mucosal folds.
6. Patient profiles
The data collected included age, gender, body mass index 
(BMI), medical history of diabetes or hypertension, use of to-
bacco, alcohol intake, date of transplantation, baseline mainte-
nance immunosuppression (cyclosporine, tacrolimus, sirolimus, 
azathioprine, or mycophenolate mofetil [MMF]), reflux-related 
symptom, and date of upper endoscopy.
7. Statistical analysis
Statistical analysis was performed using a chi-square test for 
comparison of the discrete variables, and a t-test was used for 
comparison of continuous variables. The continuous variables 
measured in this study were expressed as the mean±SD. Signifi-
cant variables in the univariate analyses (p<0.05) were entered 
into a multivariate model. Multivariate analysis was performed 
using logistic regression. For each variable, the odds ratio (OR) 
and 95% confidence interval (CI) were given. A two-tailed p-
value <0.05 was considered statistically significant. Statistical 
analysis was conducted using PASW Statistics version 17.0 
(SPSS Inc., Chicago, IL, USA).
RESULTS
1. Case-control comparisons
A comparison of patient profiles and endoscopic findings 
between SOT and control groups is shown in Table 1. BMI was 
significantly lower in the patients compared to the controls 
(p=0.031), whereas the frequency of hiatal hernia was almost 
equal in both the groups. Thirty-seven (17.2%) and 13 (6.2%) 
cases of EE were detected in the SOT and control groups, re-
spectively (p<0.001). A higher incidence of severe graded 
esophagitis was also found in the SOT group, but this difference 
was not statistically significant (11.4% vs 0%, p=0.232). In addi-
tion, there was no significant difference in the prevalence of BE 
between the SOT and control groups (1.1% vs 1.6%, p=0.727). 
The mean durations from baseline upper endoscopy to second 
endoscopy in the SOT group and control group were 23.9±7.9 
and 24.9±7.8 months, respectively (p=0.371).
2. Risk factors for EE
Based on the univariate analysis for risk factors, EE was asso-
ciated with age, BMI, presence of hiatal hernia, presence of BE, 
and transplantation (Table 2). Based on the multivariate logistic 
regression analyses, old age (OR, 1.12; 95% CI, 1.07 to 1.19), 
high BMI (OR, 1.28; 95% CI, 1.06 to 1.45), presence of hiatal 
hernia (OR, 4.98; 95% CI, 2.51 to 9.91), and transplantation (OR, 
6.48; 95% CI, 2.74 to 15.35) were associated with an increased 
risk for EE (Table 3). 
3. Characteristics of subjects with EE in the SOT group 
When the characteristics of individuals with or without 
Table 1. Characteristics of the Subjects
Characteristic
SOT 
(n=256)
Control 
(n=256)
p-value
Age (SD), yr 47.3 (6.9) 47.3 (6.9)  1.000
Male gender, n (%)  141 (55.1)  141 (55.1)  1.000
Body mass index (SD), kg/m2 22.2 (2.3) 23.9 (2.1)  0.031
Diabetes, n (%)   65 (25.4)  23 (9.0) <0.001
Hypertension, n (%)  103 (40.2)   48 (18.8) <0.001
Smoking habit, n (%)  24 (9.4)   36 (14.1)  0.145
Regular drinking habit, n (%)   37 (14.5)   50 (19.5)  0.136
Reflux-associated symptom, n (%)   78 (30.5)  17 (6.6) <0.001
Endoscopic interval, mo 23.9±7.9 24.9±7.8  0.371
Erosive esophagitis, n (%)
   None  212 (82.8)  240 (93.8)
<0.001
   Total   44 (17.2)  16 (6.2)
      Grade A 29 14
      Grade B 10 2
      Grade C 4 0
      Grade D 1 0
Hiatal hernia, n (%)  48 (18.8)  55 (21.5)  0.621
Barrett’s esophagus, n (%) 3 (1.1) 4 (1.6)  0.727
SOT, solid organ transplantation; SD, standard deviation.
Table 2. Clinical Characteristics of the Patients according to the Pres-
ence or Absence of Erosive Esophagitis
Characteristic
Erosive esophagitis
p-valueAbsence 
(n=452)
Presence 
(n=60)
Age (SD), yr 46.3 (6.3) 53.1 (6.8) <0.001
Male gender, n (%)  247 (53.1)   35 (58.3)  0.121
Body mass index (SD), kg/m2 22.4 (2.1) 23.8 (2.3)  0.039
Diabetes, n (%)   76 (16.8)   12 (20.0)  0.171
Hypertension, n (%)  128 (28.3)   23 (38.3)  0.078
Smoking habit, n (%)   54 (11.9)    6 (10.0)  0.989
Regular drinking habit, n (%)   78 (17.3)    9 (15.0)  0.411
Reflux-associated symptom, n (%)   50 (11.1)   45 (75.0) <0.001
Hiatal hernia, n (%)   78 (17.3)   25 (50.0) <0.001
Barrett’s esophagus, n (%)   4 (0.9)   3 (5.0)  0.046
Transplantation, n (%)  211 (46.7)   45 (75.0) <0.001
352  Gut and Liver, Vol. 6, No. 3, July 2012
EE within the SOT group were analyzed, age (p<0.001), BMI 
(p=0.001), hiatal hernia (p<0.001), duration of immunosup-
pression (p=0.006), and maintenance administration of MMF 
(p=0.006) were associated with EE, according to the univariate 
analysis (Table 4). Based on the multivariate logistic regression 
analyses, an increased risk of EE was strongly associated with 
the presence of hiatal hernia (OR, 5.84; 95% CI, 2.23 to 15.71; 
p<0.001), and MMF (OR, 4.13; 95% CI, 1.25 to 13.92; p=0.022) 
and more weakly with age (OR, 1.17; 95% CI, 1.09 to 1.29; 
p<0.001) in the SOT group (Table 5). In addition, increased du-
ration of immunosuppression was an independent factor associ-
ated with the development of EE (OR, 1.07; 95% CI, 1.04 to 1.15; 
p=0.019).
DISCUSSION
The principal finding of this study is that SOT was a signifi-
cant factor for the development of EE. The occurrence of this 
complication was found to be associated with the type of immu-
nosuppressant and the duration of immunosuppressive therapy 
in SOT recipients.
Our study showed an increased incidence of EE in SOT recipi-
ents undergoing sequential screening endoscopic examinations 
before and after transplantation. Although this increase was 
largely driven by mild-grade esophagitis, it was significantly 
higher than the prevalence in controls. Organ transplantation 
was strongly associated with EE (OR, 6.48; 95% CI, 2.74 to 
15.35) along with previously identified factors such as age, BMI, 
and hiatal hernia. There is evidence that a proportion (between 
1% and 13%) of patients with EE develop BE annually, and it 
has been shown that patients with EE are 5 times more likely 
to develop esophageal cancer. Interestingly, it was reported that 
the risk of esophageal cancer is twice as high in transplanted 
patients compared with those on the waiting list.23,24 However, 
no significant difference was identified between cases and con-
trols with regard to the incidence of BE. The nonsignificant rate 
of severe esophagitis or BE in our analysis may be attributable 
to the relatively short follow-up interval. Because it is known 
that patients who have been affected by gastroesophageal reflux 
disease for 20 years have 16.4 to 40 times greater risk of devel-
oping BE than does the general population, long-term follow-
up evaluation from SOT through EE to BE is clearly warranted.25
The genesis of SOT-related gastrointestinal complications is 
multifactorial. Multiple factors, including the stress of surgery, 
use of NSAIDs, and possible impairment of native gastroduo-
denal cytoprotection due to an azathioprine or MMF-induced 
slowing of intestinal cell turnover, contribute to ulcer forma-
tion in transplant patients.26 Data regarding the incidence of 
dyspepsia and reflux symptoms with different immunosuppres-
sive regimens are rare and inconclusive. However, preliminary 
data suggest that changes in immunosuppressive therapy could 
improve the gastrointestinal symptom burden and increase 
gastrointestinal specific health-related quality of life in those 
patients with gastrointestinal complaints.10,27 Some independent 
Table 3. Multiple Logistic Regression Analysis of the Clinical Factors 
Associated with Erosive Esophagitis
OR 95% CI p-value
Age 1.12 1.07-1.19 <0.001
Body mass index 1.28 1.06-1.45  0.002
Hiatal hernia 4.98 2.51-9.91 <0.001
Barrett’s esophagus 3.19  0.47-22.51  0.241
Transplantation 6.48  2.74-15.35 <0.001
OR, odds ratio; CI, confidence interval.
Table 4. Characteristics of the Subjects with Erosive Esophagitis in 
the SOT Group (Univariate Analyses)
Characteristic
Erosive esophagitis
p-valueAbsence
(n=211)
Presence
(n=45)
Age (SD), yr 46.1 (6.6) 51.8 (6.1) <0.001
Male gender, n (%)  115 (54.5)   26 (57.8)  0.365
Body mass index (SD), kg/m2 21.1 (2.6) 23.5 (1.9)  0.001
Diabetes, n (%)   53 (25.1)   12 (26.7)  0.731
Hypertension, n (%)   83 (39.3)   20 (44.4)  0.311
Smoking habit, n (%)  19 (9.0)    5 (11.1)  0.517
Regular drinking habit, n (%)   30 (14.2)    7 (15.6)  0.819
Hiatal hernia, n (%)   27 (12.8)   21 (46.7) <0.001
Barrett’s esophagus, n (%)   3 (1.4) 0  0.694
Duration of immunosuppression 
(SD), mo
24.9 (7.1) 29.2 (6.5)  0.006
Maintenance immunosuppression, n (%)
   Cyclosporine  104 (49.3)   23 (51.1)  0.857
   Tacrolimus   94 (44.5)   22 (48.9)  0.611
   Sirolimus   25 (11.8)   3 (6.7)  0.312
   Azathioprine   34 (16.1)    9 (20.0)  0.577
   Mycophenolate mofetil 85 (40.2) 29 (64.4)  0.006
SOT, solid organ transplantation; SD, standard deviation.
Table 5. Characteristics of Subjects with Erosive Esophagitis in the 
SOT Group (Multivariate Analysis)
Characteristic OR 95% CI p-value
Age 1.17 1.09-1.29 <0.001
Body mass index 1.24 0.99-1.53  0.059
Hiatal hernia 5.84  2.23-15.71 <0.001
Duration of immunosuppression 1.07 1.04-1.15  0.019
Mycophenolate mofetil 4.13  1.25-13.92  0.022
SOT, solid organ transplantation; OR, odds ratio; CI, confidence inter-
val.
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factors influencing the development of EE after SOT were iden-
tified in our study. It has previously been shown that treatment 
with MMF is associated with frequent gastrointestinal adverse 
events. Although data from randomized-clinical trials are lack-
ing, a substantial body of evidence from retrospective studies 
and registry database analyses indicates that gastrointestinal 
complications in renal transplant patients necessitate MMF dose 
reduction or discontinuation in a high proportion of cases.27,28 
Our study showed that duration of immunosuppression and 
maintenance of MMF was significantly associated with EE after 
organ transplantation. This should be considered in screen-
ing for post-transplant complications. However, it is not clear 
whether MMF exerts a direct effect, or whether EE developed 
secondary to functional gastrointestinal problems induced by 
MMF. It was known that MMF had the potential to cause toxic 
injury throughout the gastrointestinal tract. Within the upper 
gastrointestinal tract, MMF was associated with topical irrita-
tion and damage, leading to NSAID-like pathology, including 
esophageal and duodenal ulcers, and also reactive gastropathy, 
which appears to be a common manifestation of MMF. Within 
the lower gastrointestinal tract, MMF-induced pathology ap-
pears to be related mainly to its antimetabolite effects, giving 
biopsies from the colon and ileum Graft-versus-Host disease-
like properties, including mild architectural changes with dilated 
damaged crypts, lamina propria edema, increased crypt epithe-
lial apoptosis, and patchy neutrophilic inflammation.29
The main limitations of our investigation are the short dura-
tion of follow-up and a rather small number of cases. In ad-
dition, our study was a retrospective, observational study in 
which the need for screening endoscopy was determined by 
the endoscopist. Endoscopic diagnosis of BE was a problematic 
limitation of retrospective design. Nevertheless, this is the first 
case-control study of EE associated with SOT. The results of this 
study warrant a much larger prospective study to confirm these 
observations.
In conclusion, there was a significant increase in the inci-
dence (OR, 6.49) of endoscopic findings of EE in SOT recipients, 
compared with a control population. However, we did not iden-
tify a significant association of BE with SOT. Other factors, in-
cluding age, presence of hiatal hernia, duration of immunosup-
pression, and maintenance of MMF, had significant influences 
on EE in SOT recipients.
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